Table 2.
Characteristics
|
OR
|
95%CI
|
P value
|
Age (years) | 0.962 | (0.916-1.012) | 0.133 |
Gender | 1.692 | (0.588-4.870) | 0.329 |
Family history of HBV infection | 0.655 | (0.227-1.890) | 0.434 |
Characteristics at the initiation of peg-IFN-α | |||
HBsAg level, IU/mL | 1.000 | (1.000-1.000) | 0.398 |
HBsAb negative | 0.933 | (0.107-8.130) | 0.950 |
HBV DNA positive | 0.514 | (0.176-1.506) | 0.225 |
HBeAg positive | 1.448 | (0.302-6.934) | 0.643 |
Peg-IFN-α-2a | 1.624 | (0.558-4.730) | 0.374 |
Peg-IFN-α monotherapy | 0.588 | (0.224-1.546) | 0.282 |
Treatment time of peg-IFN-α (weeks) | 1.014 | (0.992-1.035) | 0.217 |
Total duration of peg-IFN-α (weeks) | 0.999 | (0.975-1.024) | 0.9570 |
Consolidation time < 12 weeks | 25.636 | (7.039-93.356) | < 0.001 |
Characteristics at the cessation of peg-IFN-α | |||
Without HBsAg seroconversion | 5.252 | (1.684-16.376) | 0.004 |
HBsAb, mIU/mL | 0.952 | (0.914-0.992) | 0.018 |
HBsAb < 35.3 mIU/mL | 9.705 | (2.098-44.883) | 0.004 |
HBsAb disappeared during the follow-up | 14.500 | (1.513-138.972) | 0.020 |
ALT level at baseline, IU/L | 1.011 | (1.001-1.021) | 0.127 |
FibroScan values at baseline (kPa) | 1.314 | (0.791-2.183) | 0.292 |
HBV: Hepatitis B virus; Peg-IFN-α: Peginterferon alpha; HBsAg: Hepatitis B surface antigen; HBsAb: Hepatitis B surface antibody; ALT: Alanine aminotransferase; OR: Odds ratio.